A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Steegen, Kim ^a   Bronze, Michelle ^b   Van Craenenbroeck, Elke ^a   Winters, Bart ^a   Van der Borght, Koen ^a   Wallis, Carole L ^b   Stevens, Wendy ^c   Rinke de Wit, Tobias F ^d   Stuyver, Lieven J ^a  

^a Tibotec Virco Virology BVBA ^*  (Belgium)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TRANSCRIPTASE;

AMINO ACID SEQUENCE; ARTICLE; CODON; COMPARATIVE STUDY; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION;

EID: 77957903817     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-38     Document Type: Article

References (23)

1. DHHS Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2008, DHHS.
2. EACS Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2008. 2008, EACS.
3. WHO Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach. 2006, Geneva: World Health Organization, WHO.
4. WHO New WHO Recommendations: Antiretroviral therapy for adults and adolescents. 2009, Geneva: WHO, WHO.
5. WHO Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003, Geneva: World Health Organization, WHO.
6. WHO/UNAIDS/UNICEF Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. 2009, Geneva: WHO, WHO/UNAIDS/UNICEF.
7. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis 2007, 11:413-416. 10.1016/j.ijid.2006.11.003, 17331776.
8. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23:1127-1134. 10.1097/QAD.0b013e32832ac34e, 2896488, 19417582.
9. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008, 22:1971-1977. 10.1097/QAD.0b013e32830e4cd8, 18784460.
10. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 49:477-484. 10.1097/QAI.0b013e318186eb18, 18989232.
11. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009, 23:697-700. 10.1097/QAD.0b013e3283262a78, 2720562, 19209067.
12. PharmAccess 2009, Amsterdam, PharmAccess., http://www.arta-africa.org
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009, 17:138-145.
14. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10:155-166. 10.1016/S1473-3099(09)70328-7, 20185094.
15. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008, 46:1589-1597. 10.1086/587109, 2692213, 18419495.
16. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009, 14:523-531.
17. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010, 53:480-484. 10.1097/QAI.0b013e3181bc478b, 19801944.
18. Steegen K, Bronze M, Van Craenenbroeck E, Stevens W, Rinke de Wit TF, Stuyver LJ. An affordable genotypic HIV drug resistance protocol for truncated reverse transcriptase compatible to the vircoTYPE prediction tool (O_4). 3rd International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings 2009, Lusaka, Zambia.
19. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007, 145:47-55. 10.1016/j.jviromet.2007.05.009, 17574687.
20. Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods 2009, 162:101-108. 10.1016/j.jviromet.2009.07.023, 19654022.
21. Verlinden Y, Vermeiren H, Lecocq P, Bacheler L, McKenna P, Vanpachtenbeke M, et al. Assessment of the Antivirogram® performance over time including a revised definition of biological test cut-off values. XIVth International HIV Drug Resistance Workshop 2005, Québec City, Québec, Canada.
22. Stanford 1998, Palo Alto, California: Stanford University, Stanford., http://hivdb.stanford.edu/
23. PharmAccess Amsterdam, PharmAccess., http://www.pharmaccess.org/Default.asp?Page=126